WINTON GROUP Ltd Buys Shares of 83,000 Oric Pharmaceuticals, Inc. $ORIC

WINTON GROUP Ltd bought a new position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 83,000 shares of the company’s stock, valued at approximately $899,000. WINTON GROUP Ltd owned 0.08% of Oric Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of ORIC. BlackRock Inc. acquired a new position in shares of Oric Pharmaceuticals in the 2nd quarter valued at $73,904,000. Siren L.L.C. raised its stake in Oric Pharmaceuticals by 197.6% during the 1st quarter. Siren L.L.C. now owns 2,998,192 shares of the company’s stock worth $37,987,000 after buying an additional 1,990,617 shares during the period. Dimensional Fund Advisors LP raised its stake in Oric Pharmaceuticals by 19.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,471,290 shares of the company’s stock worth $18,637,000 after buying an additional 244,060 shares during the period. Bank of America Corp DE lifted its holdings in Oric Pharmaceuticals by 105.5% during the first quarter. Bank of America Corp DE now owns 1,043,159 shares of the company’s stock worth $13,217,000 after acquiring an additional 535,649 shares in the last quarter. Finally, Algert Global LLC lifted its holdings in Oric Pharmaceuticals by 791.3% during the second quarter. Algert Global LLC now owns 1,215,293 shares of the company’s stock worth $13,162,000 after acquiring an additional 1,078,943 shares in the last quarter. 95.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ORIC. Benchmark restated a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th. Stifel Nicolaus assumed coverage on Oric Pharmaceuticals in a research report on Friday, June 12th. They issued a “buy” rating and a $14.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Finally, HC Wainwright increased their target price on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Oric Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $19.60.

Oric Pharmaceuticals Trading Up 5.1%

ORIC opened at $12.65 on Tuesday. The stock has a market capitalization of $1.31 billion, a P/E ratio of -9.37 and a beta of 1.00. Oric Pharmaceuticals, Inc. has a 12 month low of $7.23 and a 12 month high of $14.93. The firm’s fifty day simple moving average is $12.40 and its 200 day simple moving average is $10.87.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). On average, equities research analysts predict that Oric Pharmaceuticals, Inc. will post -1.53 EPS for the current fiscal year.

Insider Buying and Selling at Oric Pharmaceuticals

In related news, CFO Dominic Piscitelli sold 77,000 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $13.69, for a total transaction of $1,054,130.00. Following the completion of the transaction, the chief financial officer directly owned 69,828 shares in the company, valued at approximately $955,945.32. This trade represents a 52.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.70% of the stock is owned by corporate insiders.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. The company seeks to address treatment resistance by targeting biological mechanisms that allow tumors to survive or evade existing therapies, with an emphasis on restoring or enhancing the effectiveness of anti-cancer treatment.

Oric’s research and development portfolio has included small-molecule drug candidates aimed at targets such as CD73 and the polycomb repressive complex 2 (PRC2).